The Medical Letter on Drugs and Therapeutics
Drugs for ADHD
The full article is available to subscribers Subscriber Login   

Attention-deficit/hyperactivity disorder (ADHD) is a disruptive behavior disorder that has been diagnosed in up to 10% of school-age children in the US, most often in boys, and frequently persists into adulthood.1,2 A recent study in a large Danish cohort found that ADHD was associated with increased mortality in children, adolescents, and adults, mainly due to accidents.3 Pharmacologic treatment of ADHD has been reported to lower the risk of serious traffic accidents and criminal behavior.4,5

The drugs approved by the FDA for treatment of ADHD are listed in Table 1. None of these agents (except for short-acting dextroamphetamine) are approved for use in children <6 years old.


All of the stimulants used for treatment of ADHD are classified as schedule II ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Drugs for ADHD
Article code: 1464a
 Electronic, downloadable article - $25